세계의 우블리툭시맙(Ublituximab) 시장 보고서(2025년)

Ublituximab is a monoclonal antibody that targets the CD20 protein on the surface of B-cells, helping to reduce abnormal or overactive B-cell activity. It binds to these cells and promotes their destruction through immune system mechanisms, such as antibody-dependent cellular cytotoxicity. Ublituximab is primarily developed for the treatment of certain blood cancers and for modulating immune responses to manage disease progression effectively.

The primary formulation types of ublituximab are intravenous (IV) and pre-filled syringes. Intravenous administration delivers medication directly into the bloodstream for fast and controlled treatment. Ublituximab is indicated for conditions such as chronic lymphocytic leukemia, multiple sclerosis, and non-Hodgkin lymphoma. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Key end-users include hospitals, specialty clinics, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The ublituximab market research report is one of a series of new reports from The Business Research Company that provides ublituximab market statistics, including ublituximab industry global market size, regional shares, competitors with the ublituximab market share, ublituximab market segments, market trends, and opportunities, and any further data you may need to thrive in the ublituximab industry. This ublituximab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ublituximab market size has grown rapidly in recent years. It will grow from $1.11 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. Growth in the historic period was driven by increasing awareness of disease burden, rising adoption of monoclonal antibody therapies, growing healthcare expenditure, expansion of hospital and clinical infrastructure, and higher prevalence of autoimmune disorders.

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.00 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. Growth in the forecast period is expected to be supported by rising demand for targeted therapies, expansion of specialty care services, increased research funding, a growing patient population in emerging markets, and a greater number of healthcare partnerships. Key trends anticipated for the forecast period include advancements in monoclonal antibody therapies, developments in drug delivery systems, increased investment in research and development for new treatments, innovation in treatment protocols, and progress in digital health platforms.

The increasing incidence of autoimmune disorders is expected to drive growth in the ublituximab market in the coming years. Autoimmune disorders involve the immune system mistakenly attacking healthy cells or disruptions in blood cell production and function. The rise in these conditions is mainly due to enhanced diagnostic capabilities and greater awareness, as healthcare systems have improved their ability to detect previously undiagnosed cases through advanced testing and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, manages autoimmune disorders by selectively depleting harmful B cells, which reduces abnormal immune activity and malignant cell growth. For example, in November 2024, Versorgungsatlas.de, a government organization based in Germany, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61 percent. Therefore, the rising incidence of autoimmune disorders is supporting growth in the ublituximab market.

Key players in the ublituximab market are focusing on next-generation monoclonal antibodies to increase treatment effectiveness, minimize side effects, and improve patient convenience. These advanced antibodies are engineered for better targeting, potency, or safety, thereby enhancing treatment outcomes and offering more convenient dosing schedules. For instance, in January 2023, TG Therapeutics Inc., a biopharmaceutical company based in the United States, launched BRIUMVI (ublituximab-xiiy) for treating adults with relapsing forms of multiple sclerosis. The treatment offers a one-hour infusion and a comprehensive patient support program to boost accessibility and adherence. BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody designed to efficiently eliminate B cells, lowering relapse rates and disease activity in patients with relapsing multiple sclerosis, while also reducing side effects and providing a more convenient dosing option compared to traditional therapies. The drug works by binding to a specific epitope on CD20-expressing B cells, causing their targeted removal through antibody-dependent cellular cytotoxicity and apoptosis, which helps regulate the autoimmune response behind multiple sclerosis.

In August 2023, TG Therapeutics Inc. partnered with Neuraxpharm Group to commercialize BRIUMVI outside the United States and expand its reach in Europe. This collaboration aims to make BRIUMVI accessible to patients beyond the U.S., utilizing Neuraxpharm's extensive expertise in European neurology and established presence across more than 20 countries to ensure a swift and effective launch. TG Therapeutics benefits from upfront payments, milestone-based earnings, tiered royalties on sales, and retains strategic flexibility to regain commercial rights if control changes. Neuraxpharm Group is a pharmaceutical company based in Germany that specializes in treatments for central nervous system disorders.

Major players in the ublituximab market are Samsung Biologics Co. Ltd., Neuraxpharm Group GmbH, TG Therapeutics Inc.

North America was the largest region in the ublituximab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ublituximab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ublituximab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ublituximab market consists of sales of azer-cel and tg-1701. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ublituximab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ublituximab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ublituximab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ublituximab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation Type: Intravenous; Pre-Filled Syringes
• 2) By Indication: Chronic Lymphocytic Leukemia; Multiple Sclerosis; Non-Hodgkin Lymphoma
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutes
• Subsegments:
• 1) By Intravenous: Single Dose Vials; Multi Dose Vials; Lyophilized Powder; Liquid Solution
• 2) By Pre Filled Syringes: Standard Pre Filled Syringes; Safety Engineered Pre Filled Syringes; Disposable Pre Filled Syringes; Reusable Pre Filled Syringes
• Companies Mentioned: Samsung Biologics Co. Ltd.; Neuraxpharm Group GmbH; TG Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ublituximab Market Characteristics

3. Ublituximab Market Trends And Strategies

4. Ublituximab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Ublituximab Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ublituximab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ublituximab Market Growth Rate Analysis
• 5.4. Global Ublituximab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ublituximab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ublituximab Total Addressable Market (TAM)

6. Ublituximab Market Segmentation

• 6.1. Global Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Pre-Filled Syringes
• 6.2. Global Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Lymphocytic Leukemia
• Multiple Sclerosis
• Non-Hodgkin Lymphoma
• 6.3. Global Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Ublituximab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• 6.5. Global Ublituximab Market, Sub-Segmentation Of Intravenous, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Dose Vials
• Multi Dose Vials
• Lyophilized Powder
• Liquid Solution
• 6.6. Global Ublituximab Market, Sub-Segmentation Of Pre Filled Syringes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Pre Filled Syringes
• Safety Engineered Pre Filled Syringes
• Disposable Pre Filled Syringes
• Reusable Pre Filled Syringes

7. Ublituximab Market Regional And Country Analysis

• 7.1. Global Ublituximab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ublituximab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ublituximab Market

• 8.1. Asia-Pacific Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ublituximab Market

• 9.1. China Ublituximab Market Overview
• 9.2. China Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ublituximab Market

• 10.1. India Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ublituximab Market

• 11.1. Japan Ublituximab Market Overview
• 11.2. Japan Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ublituximab Market

• 12.1. Australia Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ublituximab Market

• 13.1. Indonesia Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ublituximab Market

• 14.1. South Korea Ublituximab Market Overview
• 14.2. South Korea Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ublituximab Market

• 15.1. Western Europe Ublituximab Market Overview
• 15.2. Western Europe Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ublituximab Market

• 16.1. UK Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ublituximab Market

• 17.1. Germany Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ublituximab Market

• 18.1. France Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ublituximab Market

• 19.1. Italy Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ublituximab Market

• 20.1. Spain Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ublituximab Market

• 21.1. Eastern Europe Ublituximab Market Overview
• 21.2. Eastern Europe Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ublituximab Market

• 22.1. Russia Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ublituximab Market

• 23.1. North America Ublituximab Market Overview
• 23.2. North America Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ublituximab Market

• 24.1. USA Ublituximab Market Overview
• 24.2. USA Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ublituximab Market

• 25.1. Canada Ublituximab Market Overview
• 25.2. Canada Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ublituximab Market

• 26.1. South America Ublituximab Market Overview
• 26.2. South America Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ublituximab Market

• 27.1. Brazil Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ublituximab Market

• 28.1. Middle East Ublituximab Market Overview
• 28.2. Middle East Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ublituximab Market

• 29.1. Africa Ublituximab Market Overview
• 29.2. Africa Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ublituximab Market Competitive Landscape And Company Profiles

• 30.1. Ublituximab Market Competitive Landscape
• 30.2. Ublituximab Market Company Profiles
  • 30.2.1. Samsung Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Neuraxpharm Group GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. TG Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

32. Global Ublituximab Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ublituximab Market

34. Recent Developments In The Ublituximab Market

35. Ublituximab Market High Potential Countries, Segments and Strategies

• 35.1 Ublituximab Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ublituximab Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ublituximab Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer